Stem Cells http://www.peprotech.com/
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

First published online October 12, 2006
OPEN ACCESS ARTICLE
This Article
Free via Open Access: OA
Right arrow Full Text (PDF)
Right arrowOA All Versions of this Article:
2006-0452v1
25/2/380    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dunlop, E. A.
Right arrow Articles by Lappin, T. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dunlop, E. A.
Right arrow Articles by Lappin, T. R.
Submitted on July 20, 2006
Accepted on October 6, 2006

Cancer Stem Cells

Impaired Downregulation Following Erythropoietin Receptor Activation in Non-Small Cell Lung Carcinoma

Elaine A. Dunlop 1*, A. Peter Maxwell 2, Terence R. Lappin 1

1 Haematology Research Group, Queen's University, Belfast, United Kingdom
2 Centre for Cancer Research and Cell Biology, and Nephrology Research Group, Queen's University, Belfast, United Kingdom

* To whom correspondence should be addressed. E-mail: e.dunlop{at}qub.ac.uk.


  Abstract

Recent evidence confirms the presence of erythropoietin receptors on a variety of cancer cells. This has raised concerns about the use of erythropoiesis stimulating agents (ESAs) in the treatment of cancer-related anemia. Having previously identified expression of functional erythropoietin receptors in a non-small cell lung carcinoma cell line, H838, which activated key signaling pathways in response to erythropoietin stimulation, we now demonstrate impaired downregulation of the erythropoietin receptor in these tumor cells. The erythropoietin receptor is not ubiquitinated following erythropoietin stimulation in this cancer cell line and there is no turnover of the receptor in either unstimulated or stimulated cells. Compounding this blunted response is impaired SOCS3 induction downstream of erythropoietin stimulation and an extremely delayed SOCS1 response. If this finding in non-small cell lung carcinoma is a widespread phenomenon then impaired erythropoietin receptor downregulation and degradation in tumor cells has clinical implications for those patients receiving erythropoiesis stimulating agents for cancer-related anemia.

Key Words. erythropoietin, receptor, lung carcinoma, downregulation




This article has been cited by other articles:


Home page
 BloodHome page
J. H. Lin, E. J. Kim, A. Bansal, J. Seykora, S. K. Richardson, X.-Y. Cha, S. Zafar, S. Nasta, M. Wysocka, B. Benoit, et al.
Clinical and in vitro resistance to bexarotene in adult T-cell leukemia: loss of RXR-{alpha} receptor
Blood, September 15, 2008; 112(6): 2484 - 2488.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. O. Arcasoy
Erythropoiesis-Stimulating Agent Use in Cancer: Preclinical and Clinical Perspectives
Clin. Cancer Res., August 1, 2008; 14(15): 4685 - 4690.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
C. A. Blau
Erythropoietin in Cancer: Presumption of Innocence?
Stem Cells, August 1, 2007; 25(8): 2094 - 2097.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
T. R. J. Lappin, A. P. Maxwell, and P. G. Johnston
In Reply
Oncologist, August 1, 2007; 12(8): 1032 - 1034.
[Full Text] [PDF]

Home page
 The OncologistHome page
T. R. Lappin, A. P. Maxwell, and P. G. Johnston
Warning Flags for Erythropoiesis-Stimulating Agents and Cancer-Associated Anemia
Oncologist, April 1, 2007; 12(4): 362 - 365.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
STEM CELLS THE ONCOLOGIST CME ALPHAMED PRESS JOURNALS
http://www.peprotech.com/
Copyright © 2006 by AlphaMed Press.